(Q34239875)

31 July 2017

1 reference

title

Pathophysiology of chronic heart failure. (English)

1 reference

31 July 2017

0 references

1 reference

chronic heart failure

1 reference

Francis GS

1

1 reference

PubMed ID

11334774

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

American Journal of Medicine

31 July 2017

1 reference

31 July 2017

110 Suppl 7A

1 reference

31 July 2017

37S-46S

1 reference

Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The development of positive inotropic agents for chronic heart failure: how have we gone astray?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Left ventricular hypertrophy: an initial response to myocardial injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Epidemiology of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Epidemiology of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Chronic heart failure in the United States: a manifestation of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Structural basis of end-stage failure in ischemic cardiomyopathy in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Post-infarction myocardial remodelling: why does it happen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Apoptosis in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Apoptosis in myocytes in end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The matrix-degrading metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Matrix metalloproteinases and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The cellular basis of dilated cardiomyopathy in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Patterns of myocardial fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Fibrillar collagen and remodeling of dilated canine left ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Myocardial fibrosis: functional significance and regulatory factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Myocyte nuclear and possible cellular hyperplasia contribute to ventricular remodeling in the hypertrophic senescent heart in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

7 January 2021

Death by dozens of cuts

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Cell death and the caspase cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Heart failure from the point of view of quantitative anatomy∗

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Mechanical activation of signaling pathways in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Transgenic Galphaq overexpression induces cardiac contractile failure in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Transcriptional regulation during cardiac growth and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Functional significance of alterations in cardiac contractile protein isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Increased plasma concentrations of endothelin in congestive heart failure in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Endothelins. Myocardial actions of a new class of cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Role of nitric oxide in the regulation of myocardial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Nitric oxide and cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Expression of inducible nitric oxide synthase in human heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

beta-adrenergic receptor blockade in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Pheochromocytoma masquerading as a cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Digoxin. A neurohormonal modulator in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Digoxin reduces cardiac sympathetic activity in severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

New insight into the role of enhanced adrenergic receptor-effector coupling in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

Molecular and cellular biology of heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900385-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00385-4

1 reference

31 July 2017

1 reference

PubMed ID

11334774